ABSTRACT
B-cell acute lymphoblastic leukemia (B-ALL) is a hematologic disorder characterized by the abnormal proliferation and accumulation of immature B-lymphoblasts arrested at various stages of differentiation. Despite advances in treatment, a significant percentage of pediatric patients with precursor B-ALL still relapse. Therefore, alternative therapies are needed to improve the cure rates for pediatric patients. TPEN (N, N, N', N'-tetrakis(2-pyridylmethyl)-ethylenediamine) is a pro-oxidant agent capable of selectively inducing apoptosis in leukemia cell lines. Consequently, it has been suggested that TPEN could be a potential agent for oxidative therapy. However, it is not yet known whether TPEN can selectively destroy leukemia cells in a more disease-like model, for example, the bloodstream and bone marrow (BM), ex vivo. This investigation is an extension of a previous study that dealt with the effect of TPEN on ex vivo isolated/purified refractory B-ALL cells. Here, we evaluated the effect of TPEN on whole BM from nonleukemic patients (control) or pediatric patients diagnosed with de novo B-ALL or refractory B-ALL cells by analyzing the hematopoietic cell lineage marker CD34/CD19. Although TPEN was innocuous to nonleukemic BM (n = 3), we found that TPEN significantly induced apoptosis in de novo (n = 5) and refractory B-ALL (n = 6) leukemic cell populations. Moreover, TPEN significantly increased the counts of cells positive for the oxidation of the stress sensor protein DJ-1, a sign of the formation of H2O2, and significantly increased the counts of cells positive for the pro-apoptotic proteins TP53, PUMA, and CASPASE-3 (CASP-3), indicative of apoptosis, in B-ALL cells. We demonstrate that TPEN selectively eliminates B-ALL cells (CD34 + /CD19 +) but no other cell populations in BM (CD34 + /CD19-; CD34-/CD19 + ; CD34-/CD19-) independent of age, diagnosis status (de novo or refractory), sex, karyotype, or immunophenotype. Understanding TPEN-induced cell death in leukemia cells provides insight into more effective therapeutic oxidation-inducing anticancer agents.
Subject(s)
Bone Marrow , Precursor Cell Lymphoblastic Leukemia-Lymphoma , Antigens, CD19/metabolism , Bone Marrow/metabolism , Child , Ethylenediamines , Humans , Hydrogen Peroxide/metabolism , Immunophenotyping , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapyABSTRACT
Parkinson disease (PD) is characterized by the loss of dopaminergic (DAergic) neurons linked to environmental toxicants that cause oxidative stress (OS). The aim of this investigation was to establish the molecular response of human mesenchymal stroma cells (MSCs) depleted of glutathione (GSH) by the specific inhibitor L-buthionine-sulfoximine (BSO) to 6-hydroxydopamine (6-OHDA) and/or N-acetylcysteine (NAC) co-treatment. We found that treatment with BSO (10 mM) plus 6-OHDA (200 µM) induced apoptosis in MSCs through an oxidative stress (OS) mechanism involving H2O2, reflected by the detection of dichlorofluorescein-positive (DCF+) cells and oxidation of DJ-1 Cys106-SH into DJ-1 Cys106-SO3; an almost complete reduction in glutathione peroxidase 1 (GPX1) expression; activation of the transcription factor c-JUN, the pro-apoptotic protein BAX and BH-3-only protein PUMA; loss of mitochondrial membrane potential (∆Ψm); activation of the protease caspase-3 (CASP3) and apoptosis-inducing factor (AIF); chromatin condensation; and DNA fragmentation. Strikingly, co-treatment of MSCs with NAC (5 mM) and BSO + 6-OHDA significantly reduced the expression of OS and cell death markers but were unable to restore the expression of GPX1 compared to the expression in untreated or treated cells with NAC only. These findings highlighted the importance of the maintenance of the GSH-dependent (e.g., GPX1, GSH synthesis) and -independent (e.g., ROS scavenger molecules and thiol reducing activity) antioxidant systems (e.g., NAC) in the protection of MSCs from detrimental stress stimuli, thereby increasing the survival of stromal cells.
Subject(s)
Acetylcysteine/pharmacology , Apoptosis/drug effects , Mesenchymal Stem Cells/drug effects , Antioxidants/metabolism , Buthionine Sulfoximine/metabolism , Cell Death/drug effects , Glutathione/metabolism , Glutathione Peroxidase , Humans , Hydrogen Peroxide/pharmacology , Membrane Potential, Mitochondrial/drug effects , Oxidation-Reduction , Oxidative Stress/drug effects , Oxidopamine/metabolism , Reactive Oxygen Species/metabolism , Glutathione Peroxidase GPX1ABSTRACT
BACKGROUND AIMS: Stem cell transplantation is an excellent option for regenerative or replacement therapy. However, deleterious microenvironmental and endogenous factors (e.g., oxidative stress) compromise ongoing graft survival and longevity. Therefore, (transient or stable) genetically modified cells may be reasonably thought to resist oxidative stress-induced damage. Genetic engineering of mesenchymal stromal cells (MSCs) obtained from Wharton's jelly tissue may offer some therapeutic potential. PARKIN is a multifunctional ubiquitin ligase able to protect dopaminergic cells against stress-related signaling. We, therefore, evaluated the effect of the neurotoxicant 6-hydroxydopamine (6-OHDA) on regulated cell death signaling in MSCs and investigated whether overexpression of PARKIN in MSCs was capable of modulating the effect of 6-OHDA. METHODS: We transiently transfected Wharton's jelly-derived MSCs with an mCherry-PARKIN vector using the Lipofectamine LTX method. Naïve MSCs and MSCs overexpressing PARKIN were exposed to increasing concentrations of 6-OHDA. We used light and fluorescence microscopy, flow cytometry, immunocytochemistry staining, in-cell Western and Western blot analysis. RESULTS: After 12-24 h of 6-OHDA exposure, we detected dichlorofluorescein (DCF)-positive cells (80%) indicative of reactive oxygen species (H2O2) production, reduced cell viability (40-50%), decreased mitochondrial membrane potential (ΔΨm, ~35-45%), DNA fragmentation (18-30%), and G1-arrested cell cycle in the MSCs. 6-OHDA exposure increased the expression of the transcription factor c-JUN, increased the expression of the mitochondria maintenance Phosphatase and tensin homologue-induced putative kinase 1 (PINK1) protein and increased the expression of pro-apoptotic PUMA, caspase-3 and apoptosis-inducing factor (AIF). 6-OHDA exposure also significantly augmented the oxidation of the oxidative stress sensor, DJ-1. Overexpression of PARKIN in MSCs not only significantly reduced the expression of cell death and oxidative stress markers but also significantly reduced DCF-positive cells (~50% reduction). DISCUSSION: 6-OHDA induced apoptosis in MSCs via generation of H2O2, activation of c-JUN and PUMA, mitochondrial depolarization and nuclei fragmentation. Our findings suggest that PARKIN protects MSCs against 6-OHDA toxicity by partly interacting with H2O2, reducing the expression of c-JUN, PUMA, AIF and caspase-3, and maintaining the mitochondrial ΔΨm.
Subject(s)
Apoptosis , Mesenchymal Stem Cells/metabolism , Parkinson Disease/pathology , Parkinson Disease/therapy , Ubiquitin-Protein Ligases/metabolism , Wharton Jelly/cytology , Apoptosis/drug effects , Caspase 3 , Cell Survival , Humans , Hydrogen Peroxide/pharmacology , Membrane Potential, Mitochondrial , Mesenchymal Stem Cell Transplantation , Mitochondria/metabolism , Oxidative Stress , Oxidopamine , Phenotype , Reactive Oxygen Species/metabolism , Signal TransductionABSTRACT
BACKGROUND: The human mesenchymal stem cells derived from Wharton's jelly tissue (hWJ-MSCs) represent a tool for cell-based therapies and regenerative medicine. hWJ-MSCs form neurospheres (NSs) within 3-7 days. No data is available to establish the neuro-phenotypic markers and time of formation of nerve-like (NLCs) and glial cells from NSs derived from hWJ-MSCs. NEW METHOD: hWJ-MSCs were incubated with Fast-N-Spheres medium for 24 and 72h. The new formed NSs were in turn incubated with forskolin in neurogenic NeuroForsk medium for 1-7days. RESULTS: hWJ-MSCs cultured with Fast-N-Spheres medium trans-differentiated into NSs in just 24h compared to 72h for hWJ-MSCs cultured with classic growth factor medium. The NSs generated from the Fast-N-Spheres medium expressed reduced levels SOX2, OCT4 and NANOG, as markers of pluripotency compared to undifferentiated hWJ-MSCs. The formed NSs exposed to NeuroForsk medium differentiated into NLCs in 4days as evidenced by high levels of protein expression of the neuronal markers, and no expression of the glial marker GFAP. COMPARISON WITH EXISTING METHOD(S): Currently, the formation and harvest of NSs is expensive and time consuming. Published protocols require 3-7days to form NSs from whole human umbilical cord MSCs. We report for the first time, to our knowledge, the differentiation of NSs-derived from hWJ-MSCs into NLCs. CONCLUSIONS: The fastest method to obtain NSs and NLCs from hWJ-MSCs takes only five days using the two-step incubation media Fast-N-Spheres and NeuroForsk.
Subject(s)
Cell Culture Techniques/methods , Cell Transdifferentiation/physiology , Mesenchymal Stem Cells/cytology , Mesenchymal Stem Cells/physiology , Neurons/cytology , Neurons/physiology , Adipogenesis/physiology , Blotting, Western , Colforsin , Culture Media , Fluorescent Antibody Technique , Humans , Karyotyping , Neurogenesis/physiology , Osteogenesis/physiology , Time Factors , Wharton Jelly/cytologyABSTRACT
Parkinson's disease (PD) is a common progressive neurodegenerative disorder, for which at present no causal treatment is available. On the understanding that the causes of PD are mainly oxidative stress and mitochondrial dysfunction, antioxidants and other drugs are expected to be used. In the present study, we demonstrated for the first time that pure polyphenols such as gallic acid, ferulic acid, caffeic acid, coumaric acid, propyl gallate, epicatechin, epigallocatechin, and epigallocatechin gallate protect, rescue and, most importantly, restore the impaired movement activity (i.e., climbing capability) induced by paraquat in Drosophila melanogaster, a valid model of PD. We also showed for the first time that high concentrations of iron (e.g. 15 mM FeSO(4)) are able to diminish fly survival and movement to a similar extent as (20 mM) paraquat treatment. Moreover, paraquat and iron synergistically affect both survival and locomotor function. Remarkably, propyl gallate and epigallocatechin gallate protected and maintained movement abilities in flies co-treated with paraquat and iron. Our findings indicate that pure polyphenols might be potent neuroprotective agents for the treatment of PD against stressful stimuli.
Subject(s)
Ferric Compounds/toxicity , Flavonoids/pharmacology , Neuroprotective Agents/pharmacology , Paraquat/toxicity , Phenols/pharmacology , Animals , Antioxidants/pharmacology , Disease Models, Animal , Drosophila melanogaster , Female , Motor Activity/drug effects , Oxidative Stress/drug effects , Parkinson Disease/drug therapy , Polyphenols , Survival RateABSTRACT
Cannabinoids have been shown to function as protective agents via receptor-independent and/or receptor-dependent mechanisms against stressful conditions. However, the neuroprotective mechanism of cannabinoids is far from conclusive. Therefore, the genuine antioxidant impact of cannabinoids in vivo is still uncertain. In this study, we demonstrate for the first time that CP55,940, a nonselective CB(1)/CB(2) cannabinoid receptor agonist, significantly protects and rescues Drosophila melanogaster against paraquat (PQ) toxicity via a receptor-independent mechanism. Interestingly, CP55,940 restores the negative geotaxis activity (i.e., climbing capability) of the fly exposed to PQ. Moreover, Drosophila fed with (1-200 microM) SP600125, a specific inhibitor of the stress responsive Jun-N-terminal kinase (JNK) signaling, and 20 mM PQ increased survival percentage and movement function (i.e., climbing capability) when compared to flies only treated with PQ. Taken together our results suggest that exogenous antioxidant cannabinoids can protect against and rescue from locomotor dysfunction in wild type (Canton-S) Drosophila exposed to stress stimuli. Therefore, cannabinoids may offer promising avenues for the design of molecules to prevent, delay, or ameliorate the treatment of population at high risk of suffering Parkinson disease.
Subject(s)
Cyclohexanols/administration & dosage , Herbicides/toxicity , Immunosuppressive Agents/administration & dosage , Motor Activity/drug effects , Paraquat/toxicity , Animals , Anthracenes/administration & dosage , Antioxidants/administration & dosage , Behavior, Animal/drug effects , Dose-Response Relationship, Drug , Drosophila melanogaster , Drug Interactions , Enzyme Inhibitors/administration & dosage , Feeding Behavior/drug effects , Female , Glucose/administration & dosage , Male , Survival Analysis , Time Factors , Tocopherols/administration & dosageSubject(s)
Alzheimer Disease/genetics , Genetic Predisposition to Disease , Histocompatibility Antigens Class I/genetics , Membrane Proteins/genetics , Polymorphism, Single Nucleotide/genetics , Presenilin-1/genetics , Adult , Case-Control Studies , Female , Gene Frequency , Hemochromatosis Protein , Humans , Male , Middle Aged , White People/geneticsABSTRACT
Cannabinoids have been suggested as potential neuroprotective compounds in Alzheimer's disease (AD). Despite intense investigation, the detailed intracellular mechanism(s) involved in cannabinoids survival effect remains to be elucidated. The present study shows that CP55,940 (a CB1 and CB2 agonist) and JWH-015 (a CB2 agonist) protect and rescue peripheral blood lymphocytes (PBL) from (10 microM) Abeta[(25-35)] and (50 microM) H(2)O(2)-induced apoptosis by two alternative mechanisms: (1) receptor-independent pathway, as demonstrated by no-dihydrorhodamine oxidation into fluorescent rhodamine 123 (R-123) as a result of cannabinoid inhibition of Abeta-generated H(2)O(2); (2) receptor-dependent pathway through NF-kappaB activation and p53 down regulation involving phosphoinositide 3-kinase (PI-3K), as demonstrated by using either (25 microM) LY294002 (a PI-3K inhibitor), (50 nM) pifithrin-alpha (PFT, a specific p53 inhibitor) or by using immunocytochemistry detection of NF-kappaB and p53 transcription factors activation. Importantly, cannabinoid agonists and PFT were able to protect and rescue lymphocytes pre-exposed to toxicants-, even when the three compounds were added up-to 12 h post-Abeta[(25-35)]/(H(2)O(2)) exposure. These results suggest that CP55,940/( JWH-015) protection/rescue of PBL from noxious stimuli is determined by p53 inactivation. These findings may contribute to a better understanding of the role played by cannabinoids as neuroprotective agents to target and interrupt molecular signaling that induce damage in AD disorder.
Subject(s)
Amyloid beta-Peptides/pharmacology , Apoptosis/drug effects , Cannabinoids/agonists , Hydrogen Peroxide/pharmacology , Lymphocytes/drug effects , NF-kappa B/metabolism , Peptide Fragments/pharmacology , Phosphatidylinositol 3-Kinases/metabolism , Tumor Suppressor Protein p53/metabolism , Adult , Cyclohexanes/pharmacology , Cyclohexanols , Cytoprotection/drug effects , Humans , Indoles/pharmacology , Lymphocytes/cytology , Lymphocytes/metabolism , Male , Phenols/pharmacology , Phosphoinositide-3 Kinase Inhibitors , Protein Kinase Inhibitors/pharmacology , Receptors, Cannabinoid/metabolismABSTRACT
INTRODUCTION AND OBJECTIVES: Alzheimer s disease is a neurodegenerative disorder characterized neuropathologically by beta amyloid plaques, neurofibrillary tangles, gliosis and neuronal loss. Recently, we have elucidated a molecular cascade of cell death induced by A beta 25 35 involving the activation of nuclear factor kappa B (NF kB), p53, and c Jun transcription factors in vitro. At present, no comparative reports have been published to establish a similar cell death signalization pathway in in vitro and in in vivo. The aim of this investigation was to determine if AD brains might activate NF kB, p53, c Jun, Par 4 transcription factors and to establish whether there exist a relationship between neuronal DNA damage and transcription factors activation. PATIENTS AND METHODS: We investigated Ab plaques, neurofibrillary tangles and NF kB, p53, and c Jun transcription factor activation in five cerebral regions from 3 normal subjects and from six demented patient with sporadic AD and one patient with AD familiar according to CERAD criteria. Using TUNEL we determine neuronal damage. RESULTS: We demonstrated neuronal damage in 17 out of 50 regions evaluated as TUNEL positive, and their distribution was heterogeneous in all brain regions evaluated; and the activation of NF kB, p53, c Jun and Par 4 transcription factors from case # 24 and #22, corresponding to TUNEL positive. CONCLUSIONS: We found a correlation between severity of DNA damage and nuclear activation of the transcription factors. These findings suggest that the AD brain may induce cell death by a molecular signalization similar to a non neuronal model by Ab exposure. This in situ study might validate previous Ab induced cell death observations in vitro.
Subject(s)
Alzheimer Disease/metabolism , Carrier Proteins/analysis , DNA Damage , Intracellular Signaling Peptides and Proteins , NF-kappa B/analysis , Neurons/chemistry , Proto-Oncogene Proteins c-jun/analysis , Tumor Suppressor Protein p53/analysis , Adult , Aged , Amyloid beta-Peptides/analysis , Apoptosis/physiology , Apoptosis Regulatory Proteins , Cerebral Cortex/metabolism , Cerebral Cortex/pathology , Female , Humans , In Situ Nick-End Labeling , Male , Middle Aged , Statistics as TopicABSTRACT
Introducción y objetivos. La enfermedad de Alzheimer (EA) se caracteriza neuropatológicamente por placas de Beta-amiloide, ovillos neurofibrilares (ONF), gliosis y pérdida neuronal. Recientemente, hemos elucidado una cascada de muerte celular inducida por el Alfa-Beta A25-35 que involucra la activación de los factores de transcripción nuclear B (FN-B), p53 y c-Jun in vitro. Actualmente, no se han comunicado estudios comparativos entre los eventos moleculares de muerte celular in vitro e in vivo. El objetivo fue determinar si en los cerebros con EA se activan el FN-kB, p53, c-Jun y Par-4,y establecer si esta activación se relaciona con la fragmentación del ADN neuronal. Pacientes y métodos. Se investigó la presencia de placas, ONF y activación de los factores de transcripción en cinco regiones de tejido post mortem en tres cerebros de sujetos normales, en seis pacientes diagnosticados de Alzheimer esporádico y en uno dignosticado de Alzheimer familiar con los criterios de CERAD. El daño neuronal se determinó con TUNEL. Resultados. Evidenciamos daño neuronal en 17 de 50 regiones analizadas positivas para TUNEL, con una distribución heterogénea en todas las regiones evaluadas. También se puso de manifiesto la activación del FN-kB, p53, Par-4 y c-Jun en los casos n.º 22 y 24, correspondientes a las regiones positivaspara TUNEL. Conclusión. Demostramos una correlación entre la gravedad del daño neuronal y la activación nuclear de los factores de transcripción. Estos hallazgos sugieren que en los cerebros afectados de EA se podría inducir muerte neuronal por una señalización molecular similar a modelos no neuronales por exposición al A25-35. Este estudio in situ valida observaciones previas de muerte celular inducida por el A25-35 in vitro (AU)
Subject(s)
Middle Aged , Adult , Aged , Male , Female , Humans , DNA Damage , Statistics , NF-kappa B , Amyloid beta-Peptides , Apoptosis , Neurons , In Situ Nick-End Labeling , Cerebral Cortex , Carrier Proteins , Alzheimer Disease , Proto-Oncogene Proteins c-jun , Tumor Suppressor Protein p53ABSTRACT
OBJECTIVES: In this article, the authors analyzed critically the morphological and biochemical evidences of cell death by apoptosis from postmortem studies in Alzheimer s, Parkinson s, Huntington s and Wilson s diseases. DEVELOPMENT: During the last few years, apoptosis has been postulated as a type of neuronal death responsible for the neurodegenerative process in those heterogeneous, chronic and progressive neurological disorders, which are characterized by a selective and a symmetric loss of neurons in motor, sensory or cognitive systems. With regard to neuronal death mechanism and the contribution of the mutated or metabolic altered proteins such as betaA, P-tau, alpha-synuclein, Parkin, Huntingtin, ATP78B, proteins in the pathogenesis of those disorders are still unknown. CONCLUSIONS: We consider that the morphological (e.g. DNA fragmentation without showing classical apoptotic morphology) and biochemical evidences are still insufficient and contradictory to formally indict apoptosis as the mechanism of neuronal cell death in those neurological disorders. The establishment of the molecular mechanisms leading neurons to cell death (by apoptosis?) could provide significant information for the design of therapeutic strategies to retard or prevent the development of such neurodegenerative diseases in affected individuals.
Subject(s)
Apoptosis/physiology , Neurodegenerative Diseases/pathology , Neurons/pathology , Alzheimer Disease/pathology , Hepatolenticular Degeneration/pathology , Humans , Huntington Disease/pathology , Parkinson Disease/pathologyABSTRACT
Objetivos. En este artículo, los autores analizan críticamente las evidencias morfológicas y bioquímicas de muerte por apoptosis en tejido cerebral post mórtem de las enfermedades neurodegenerativas de Alzheimer, de Parkinson, de Huntington y de Wilson. Desarrollo. Durante los últimos años, la apoptosis se ha postulado como el tipo de muerte neuronal responsable del proceso de neurodegeneración en estos trastornos neurológicos heterogéneos, crónicos y progresivos, los cuales se caracterizan por la pérdida selectiva y simétrica de las neuro nas motoras, sensoriales y de los sistemas cognitivos. Con respecto al mecanismo de muerte neuronal y la contribución de las proteínas mutadas o alteradas metabólicamente, tales como la bA, la P-tau, la a-sinucleína, la parkina, la huntingtina y la ATP-7B en la patogénesis de estos trastornos, todavía no se han establecido. Conclusiones. Consideramos que las evidencias morfológicas (p. ej., la fragmentación del ADN sin la observación de la morfología clásica apoptótica) y bioquímicas son insuficientes y contradictorias para implicar formalmente a la apoptosis como el mecanismo de muerte neuronal en estos trastornos neurológicos. Por lo tanto, el esclarecimiento de los mecanismos moleculares de muerte neuronal (¿por apoptosis?) aportaría información esencial en el diseño de estrategias terapéuticas que retrasen o prevengan el curso de las enfermedades neurodegenerativas en los individuos afectados (AU)
Subject(s)
Humans , Neurodegenerative Diseases , Apoptosis , Neurons , Parkinson Disease , Alzheimer Disease , Hepatolenticular Degeneration , Huntington DiseaseABSTRACT
Although there have been experimental approaches to understanding the etiology of Parkinson's disease, the cause of cell degeneration in this neurological disorder remains a mystery. Herein, a hypothetical model is proposed to explain the mechanism leading neurons to die. The model is based on recent experimental evidence and it attempts to dissect the actions of dopamine and metal ions as potential triggers for the activation of an ordered cascade of events of the cell death machinery.
Subject(s)
Biogenic Monoamines/toxicity , Models, Neurological , Neurons/pathology , Parkinson Disease/pathology , Parkinson Disease/physiopathology , Animals , Biogenic Monoamines/physiology , Cell Death , Dopamine/physiology , Humans , MetalsABSTRACT
Dopamine (DA) in combination with iron (Fe(2+)) has been demonstrated to induce apoptosis in neuronal-like PC12 cells by an oxidative stress mechanism. To get a better insight of cell death and protective mechanisms in DA/Fe(2+)-induced toxicity, we investigated the effects of DA/Fe(2+) and the antioxidant action of 17 beta-estradiol (E2) in peripheral blood lymphocytes (PBL). We found that DA/Fe(2+)-induces apoptosis in PBL via a hydrogen peroxide (H(2)O(2))-mediated oxidative mechanism, which in turn triggers a cascade of molecular events requiring RNA and de novo protein synthesis. We have also demonstrated that E2 prevents significantly DA/Fe(2+)-induced apoptosis in PBL by directly inhibiting the intracellular accumulation of peroxides generated by DA/Fe(2+)-reaction. This protective activity is independent of the presence or activation of the estrogen receptors (ERs). These data further support and validate our previous hypothesis that DA/Fe(2+)/H(2)O(2) could be a general mediator of oxidative stress through a common cell death mechanism in both neuronal and nonneuronal cells. These findings may be particularly relevant to the potential approaches to rescue and prolong the survival of neurons by estrogens in patients with Parkinson's disease (PD).
Subject(s)
Apoptosis/drug effects , Apoptosis/genetics , Dopamine/pharmacology , Estradiol/genetics , Estradiol/pharmacology , Genomics , Iron/pharmacology , Lymphocytes/drug effects , Parkinson Disease/genetics , Adult , Cycloheximide/pharmacology , DNA Fragmentation/drug effects , DNA Fragmentation/genetics , Dactinomycin/pharmacology , Electrophoresis, Agar Gel , Humans , Hydrogen Peroxide/toxicity , Lymphocytes/blood , Male , Parkinson Disease/blood , Predictive Value of Tests , Protein Synthesis Inhibitors/pharmacology , Receptors, Estrogen/drug effectsABSTRACT
Recent studies have shown that the missense mutation in presenilin-1 [E280A] increases deposition of amyloid-beta (Abeta) and neurofibrillary tangle (NFT) formation. Indeed, we only observed 10 out of 48 FAD brain sections displaying TUNEL (+) labeling, and none with the classical apoptotic morphology. These results may indicate that DNA fragmentation is not a generalized phenomenon in early-onset FAD PS1 [E280A] patients or that neuronal cells are dying by a different mechanism of cell death. Taking together these findings suggest that Abeta and NFTs are not per se a causative factor to damage neuronal cells but their damage could be more related with individual neuronal vulnerability and brain aging
ABSTRACT
1. The basic etiology of Alzheimer's disease remains unknown, although four genes have so far been involved: beta-amyloid precursor protein, presenilin-1, presenilin-2 and apolipoprotein E genes. 2. The largest familial Alzheimer's disease (FAD) kindred so far reported belong to a point mutation in codon 280 that results in a glutamic acid-to-alanine substitution in presenilin-1 characterized in Antioquia, Colombia. 3. A hypothetical unified molecular mechanism model of cell death in FAD mediated by presenilin-1, beta-amyloid, and oxidative stress is proposed as an attempt to explain the mechanisms of neuronal loss in this neurodegenerative disorder.
Subject(s)
Alzheimer Disease/metabolism , Alzheimer Disease/pathology , Amyloid beta-Peptides/metabolism , Membrane Proteins/metabolism , Oxidative Stress , Alzheimer Disease/genetics , Animals , Cell Death , Humans , Neuroprotective Agents/pharmacology , Presenilin-1 , Presenilin-2ABSTRACT
1. Monoamines do not form coordination bonds with a preformed iron-serotonin-binding protein (SBP) complex, as initially believed. Instead, metals oxidize the monoamines either directly (manganese, copper) or by oxygen free radical formation (iron), the oxidation products bind covalently to SBP and the conjugates are able to undergo redox cycling. These interactions are denoted as a "molecular oxidative mechanism." 2. Dopamine in combination with iron induces lipid peroxidation and apoptosis in PC12 cells by a stress oxidative-Ca2+ independent mechanism. 3. Dopamine-iron cytotoxicity may have relevance to an understanding of the mechanism by which dopaminergic neurons are eroded in some neurodegenerative disorders.
Subject(s)
Apoptosis/physiology , Biogenic Monoamines/metabolism , Iron/metabolism , Lipid Peroxidation/physiology , Receptors, Serotonin/physiology , Animals , Cell Extracts/pharmacology , Free Radicals , Lipid Peroxidation/drug effects , PC12 Cells , Rats , Serotonin/metabolismABSTRACT
Recent studies have shown that Fe2+ increases the oxidation of monoamines such as serotonin, dopamine and related toxins and that the formed oxidation products can undergo co-valent binding to free sulphydryl groups of proteins such as actin and "serotonin binding proteins" which are present in soluble brain extracts. Here we have tested the ability of ferrous iron to induce [3H]dopamine association to cytoplasmic proteins and we have established that a similar oxidation mechanism evidenced in vitro studies could be applied in cell culture. When PC12 cells were incubated with ferrous iron (ferrocene), the binding of [3H]dopamine to proteins was found to be two fold increased with respect to control. The iron is likely to accelerate the oxidation of dopamine to produce quinones which covalently bind to proteins and induce high-molecular protein aggregates. We evidenced that dopamine/iron combination induced cell death in undifferentiated PC12 cells via an active cellular process evaluated in terms of morphological and biochemical changes indicative of apoptosis. We also demonstrated induction of lipid peroxidation when dopamine and ferrocene were present in high concentrations. Moreover, ascorbic acid diminished apoptosis but not the lipid peroxidation process. It might indicate that ferrocene and dopamine could produce oxidative stress of a different nature. These results show that the actions of dopamine and iron are essential in the induction of apoptosis and lipid peroxidation. However, there is no necessary casual link between lipid peroxidation and apoptosis. Our data also suggest that iron is capable of increasing the cytotoxicity of dopamine merely by increasing its rate of oxidation and without intervention of the monoamine oxidase B enzyme and, hence, both phenomenons may occur independently from each other in rat pheochromocytoma PC12. These observations may have relevance to the understanding of the mechanism by which dopaminergic neurones are destroyed in some neurodegenerative disorders.
Subject(s)
Apoptosis/drug effects , Dopamine/toxicity , Ferrous Compounds/toxicity , Animals , Cattle , DNA, Neoplasm/drug effects , DNA, Neoplasm/metabolism , Dopamine/metabolism , Lipid Peroxidation/drug effects , Metallocenes , Molecular Weight , Neoplasm Proteins/metabolism , Nucleosomes/drug effects , Nucleosomes/metabolism , PC12 Cells , Protein Binding , Rats , TritiumABSTRACT
It has been shown recently that the covalent binding of labelled dopamine and serotonin to serotonin binding proteins (SBP) from bovine frontal cortex is potently inhibited by their related neurotoxins. The present study reveals that the monoamine-SBP conjugates of serotonin, dopamine, and related toxins are able to catalyse redox cycling reactions. Using an improved method to detect quinoproteins in SDS-PAGE gels, we were also able to demonstrate that the redox cycling activity corresponded to two major protein components with molecular weights of 45 and 56 kDa. The covalent monoamine-SBP conjugates may be referred to as "artificial quinoproteins."